Eligo Bioscience

Eligo Bioscience was founded in 2014 as a spin-off from MIT and the Rockefeller University based on the discoveries from the Lu and Marraffini labs. The company develops a new generation of biotherapeutics that enable the expression of genetic circuits within target microbial populations and treat a wide-range of bacteria-associated unmet medical needs both in humans and animals. The company has won several international awards, has raised a US$3M seed-round in July 2015 and is currently located at Institut Pasteur in the heart of Paris.

Visit the Eligo Bioscience website

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2025 World Economic Forum